Stifel raises Buy rating on Definium Therapeutics to $60 amid GAD trial success

Definium Therapeutics Inc. (NASDAQ: DFTX) received a reiterated Buy rating from Stifel with a $60 price target, following strong Phase 3 trial results for its orally-disintegrating tablet DT120, designed to treat generalized anxiety disorder (GAD). The stock, currently trading at $39.07, has surged 322% over the past year but has declined 12% in the week leading up to the update. The company’s clinical pipeline remains a key catalyst, with a second Phase 3 readout for GAD expected later this month, following a positive Voyage trial that met its primary endpoint—a statistically significant reduction in Hamilton Anxiety Rating Scale scores for the 100µg dose over placebo. DT120 is also poised for a joint pre-NDA meeting to advance indications for major depressive disorder (MDD) and GAD, pending regulatory confirmation. Analysts have raised expectations: Canaccord Genuity increased its price target from $58 to $64 (Buy), while BofA Securities initiated coverage with a $75 target (Buy), aligning with a broader Wall Street consensus of a Strong Buy rating across a $52–$90 range. The company’s balance sheet remains robust, with more cash than debt, and its recent performance mirrors past AI-driven biotech winners like Super Micro Computer (+185%) and AppLovin (+157%), though its financial health rating from InvestingPro remains Fair. The market’s appetite for biotech innovation remains high, with Definium’s clinical milestones positioning it as a potential catalyst for further upside.